Clinical example of enhancing efficacy of paclitaxel by combining it with ramuchirumabin in the second-line chemotherapy of disseminated gastric cancer

Медицинский совет

T. A. Titova¹  N. S. Besova¹  E. V. Artamonova¹ 

[1] Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.;

关键词: gastric cancer;    ramucirumab;    second line treatment;    angiogenesis;   

DOI  :  10.21518/2079-701X-2019-10-136-140

来源: DOAJ

【 摘 要 】

The low efficacy of cytostatic therapy in mGC led to an active study of the role of molecular targets in the carcinogenesis of GC. Ramucirumab is the only neoangiogenesis inhibitor, which demonstrated its antitumor activity both as monotherapy and in combination with paclitaxel in patients with mGC. A clinical case demonstrated an example of a long-term (26+ months) response to paclitaxel therapy after it was combined with ramucirumab with an acceptable toxicity profile, which allowed a patient to participate in social activities and maintain quality of life.

【 授权许可】

Unknown